Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 5/2011

01-10-2011

What’s New in the Management of Bacterial Septic Arthritis?

Authors: Sumeet Chander, Gerald Coakley

Published in: Current Infectious Disease Reports | Issue 5/2011

Login to get access

Abstract

Septic arthritis is a common rheumatological emergency requiring prompt diagnosis and treatment, since delays in management can lead to high morbidity and mortality. In this review article, we discuss the epidemiology and recent advances in knowledge of the pathogenesis of septic arthritis, with a special emphasis on various bacterial and host factors involved in mediating the inflammatory process and the potential for targeted therapy to modulate the immune response. Recent advances in laboratory and imaging techniques are reviewed along with treatment and potential new therapies.
Literature
1.
Gupta MN, Sturrock RD, Field M. A prospective 2 year study of 75 patients with adult-onset septic arthritis. Rheumatology. 2001;40(1):24–30.PubMedCrossRef
2.
Morgan DS, Fisher D, Merianos A, Currie BJ. An 18 year clinical review of septic arthritis from tropical Australia. Epidemiol Infect. 1996;117:423–8.PubMedCrossRef
3.
Kaandorp CJE, Dinant HJ, van de Laar MAFJ, et al. Incidence and sources of native and prosthetic joint infection: a community based prospective survey. Ann Rheum Dis. 1997;56(8):470–5.PubMedCrossRef
4.
Weston VC, Jones AC, Bradbury N, et al. Clinical features and outcome of septic arthritis in a single UK Health District 1982–1991. Ann Rheum Dis. 1999;58(4):214–9.PubMedCrossRef
5.
6.
• Favero M, Schiavon F, Riato L, et al. Rheumatoid arthritis is the major risk factor for septic arthritis in rheumatological settings. Autoimmun Rev. 2008;8(1):59–61. Outlines rheumatoid arthritis as a risk factor for septic arthritis.PubMedCrossRef
7.
Smith JW, Chalupa P, Shabaz Hasan M. Infectious arthritis: clinical features, laboratory findings and treatment. Clin Microbiol Infect. 2006;12(4):309–14.PubMedCrossRef
8.
Weng C-T, Liu M-F, Lin L-H, et al. Rare coexistence of gouty and septic arthritis: a report of 14 cases. Clin Exp Rheumatol. 2009;27(6):902–6.PubMed
9.
•• Allison DC, Holtom PD, Patzakis MJ, Zalavras CG. Microbiology of bone and joint infections in injecting drug abusers. Clin Orthop Relat Res. 2010;468(8):2107–12. This paper shows MRSA as an important causative organism of septic arthritis.PubMedCrossRef
10.
Frazee BW, Fee C, Lambert L. How common is MRSA in adult septic arthritis? Ann Emerg Med. 2009;54(5):695–700.PubMedCrossRef
11.
Goldenberg DLM, Brandt KDM, Cathcart ESM, Cohen ASM. Acute arthritis caused by gram-negative bacilli: a clinical characterization. [Article]. Medicine. 1974;53(3):197–208.PubMedCrossRef
12.
Palmqvist N, Foster T, Tarkowski A, Josefsson E. Protein A is a virulence factor in Staphylococcus aureus arthritis and septic death. Microb Pathog. 2002;33(5):239–49.PubMedCrossRef
13.
Swaminathan A, Massasso D, Gotis-Graham I, Gosbell I. Fulminant methicillin-sensitive Staphylococcus aureus infection in a healthy adolescent, highlighting Panton-Valentine leucocidin syndrome. Intern Med J. 2006;36(11):744–7.PubMedCrossRef
14.
Martinez-Aguilar GM, Avalos-Mishaan AM, Hulten KP, et al. Community-acquired, methicillin-resistant and methicillin-susceptible staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J. 2004;23(8):701–6.PubMedCrossRef
15.
•• Mathews CJ, Weston VC, Jones A, et al. Bacterial septic arthritis in adults. Lancet. 2010;375(9717):846–55. A detailed and a comprehensive overview of etiopathogenesis and management of septic arthritis.PubMedCrossRef
16.
Hultgren O, Eugster HP, Sedgwick JD, et al. TNF/Lymphotoxin-alpha double-mutant mice resist septic arthritis but display increased mortality in response to Staphylococcus aureus. J Immunol. 1998;161(11):5937–42.PubMed
17.
Hultgren OH, Svensson L, Tarkowski A. Critical role of signaling through IL-1 receptor for development of arthritis and sepsis during Staphylococcus aureus infection. J Immunol. 2002;168(10):5207–12.PubMed
18.
Gjertsson I, Hultgren OH, Tarkowski A. Interleukin-10 ameliorates the outcome of Staphylococcus aureus arthritis by promoting bacterial clearance. Clin Exp Immunol. 2002;130(3):409–14.PubMedCrossRef
19.
Hultgren O, Kopf M, Tarkowski A. Outcome of Staphylococcus aureus-triggered sepsis and arthritis in IL-4-deficient mice depends on the genetic background of the host. Eur J Immunol. 1999;29(8):2400–5.PubMedCrossRef
20.
• Collins CE, La DT, Yang HT, et al. Elevated synovial expression of triggering receptor expressed on myeloid cells 1 in patients with septic arthritis or rheumatoid arthritis. Ann Rheum Dis. 2009;68(11):1768–74. A potential new diagnostic marker for septic arthritis.PubMedCrossRef
21.
Remijsen Q, Kuijpers TW, Wirawan E, et al. Dying for a cause: NETosis, mechanisms behind an antimicrobial cell death modality. Cell Death Differ. 2011;18(4):581–8.PubMedCrossRef
22.
Logters T, Paunel-Gorgulu A, Zilkens C, et al. Diagnostic accuracy of neutrophil-derived circulating free DNA (cf-DNA/NETs) for septic arthritis. J Orthop Res. 2009;27(11):1401–7.PubMedCrossRef
23.
•• Varoga D, Klostermeier E, Paulsen F, et al. The antimicrobial peptide HBD-2 and the Toll-like receptors-2 and −4 are induced in synovial membranes in case of septic arthritis. Virchows Arch. 2009;454(6):685–94. This study shows an important host defence mechanism against bacteria in septic arthritis.PubMedCrossRef
24.
Papathanasiou I, Malizos KN, Poultsides L, et al. The catabolic role of toll-like receptor 2 (TLR-2) mediated by the NF-κB pathway in septic arthritis. J Orthop Res. 2011;29(2):247–51.PubMedCrossRef
25.
Puliti M, Bistoni F, Tissi L. Lack of B7-1 and B7-2 costimulatory molecules modulates the severity of group B Streptococcus-induced arthritis. Microb Infect. 2010;12(4):302–8.CrossRef
26.
Ispahani P, Weston VC, Turner DPJ, Donald FE. Septic arthritis due to Streptococcus pneumoniae in Nottingham, United Kingdom, 1985–1998. Clin Infect Dis. 1999;29(6):1450–4.PubMedCrossRef
27.
Goldenberg DL, Cohen AS. Acute infectious arthritis. A review of patients with non-gonococcal joint infections (with emphasis on therapy and prognosis). Am J Med. 1976;60:369–77.PubMedCrossRef
28.
Gupta MN, Sturrock RD, Field M. Prospective comparative study of patients with culture proven and high suspicion of adult onset septic arthritis. Ann Rheum Dis. 2003;62(4):327–31.PubMedCrossRef
29.
Eder L, Zisman D, Rozenbaum M, Rosner I. Clinical features and aetiology of septic arthritis in northern Israel. Rheumatology. 2005;44(12):1559–63.PubMedCrossRef
30.
Coakley G, Mathews C, Field M, et al. BSR & BHPR, BOA, RCGP and BSAC guidelines for management of the hot swollen joint in adults. Rheumatology. 2006;45(8):1039–41.PubMedCrossRef
31.
Dubnov-Raz G, Scheuerman O, Chodick G, et al. Invasive Kingella kingae infections in children: clinical and laboratory characteristics. Pediatrics. 2008;122(6):1305–9.PubMedCrossRef
32.
•• Kim H, Kim J, Ihm C. The usefulness of multiplex PCR for the identification of bacteria in joint infection. J Clin Lab Anal. 2010;24(3):175–81. This study discusses an important new and rapid diagnostic tool for septic arthritis.PubMedCrossRef
33.
Sontakke S, Cadenas MB, Maggi RG, et al. Use of broad range16S rDNA PCR in clinical microbiology. J Microbiol Meth. 2009;76(3):217–25.CrossRef
34.
• Ernst AAM, Weiss SJM, Tracy LAM, Weiss NR. Usefulness of CRP and ESR in predicting septic joints. South Med J. 2010;103(6):522–6. This paper reveals interpretation and importance of traditional inflammatory markers in septic arthritis.PubMedCrossRef
35.
Li SF, Henderson J, Dickman E, Darzynkiewicz R. Laboratory tests in adults with monoarticular arthritis: can they rule out a septic joint? Acad Emerg Med. 2004;11(3):276–80.PubMedCrossRef
36.
Hugle T, Schuetz P, Mueller B, et al. Serum procalcitonin for discrimination between septic and non-septic arthritis. Clin Exp Rheumatol. 2008;26(3):453–6.PubMed
37.
Li SF, Cassidy C, Chang C, et al. Diagnostic utility of laboratory tests in septic arthritis. Emerg Med J. 2007;24(2):75–7.PubMedCrossRef
38.
Margaretten ME, Kohlwes J, Moore D, Bent S. Does this adult patient have septic arthritis? JAMA: J Am Med Assoc. 2007;297(13):1478–88.CrossRef
39.
Coutlakis PJ, Roberts WN, Wise CM. Another look at Synovial fluid leukocytosis and infection. JCR: J Clin Rheumatol. 2002;8(2):67–71.PubMedCrossRef
40.
McGillicuddy DC, Shah KH, Friedberg RP, et al. How sensitive is the synovial fluid white blood cell count in diagnosing septic arthritis? Am J Emerg Med. 2007;25(7):749–52.PubMedCrossRef
41.
Abdullah S, Young-Min SA, Hudson SJ, et al. Gross synovial fluid analysis in the differential diagnosis of joint effusion. J Clin Pathol. 2007;60(10):1144–7.PubMedCrossRef
42.
Thompson A, Mannix R, Bachur R. Acute pediatric monoarticular arthritis: distinguishing Lyme arthritis from other etiologies. Pediatrics. 2009;123:959–65.PubMedCrossRef
43.
de Murphy CA, Gemmel F, Balter J. Clinical trial of specific imaging of infections. Nucl Med Comm. 2010;31(8):726–33.CrossRef
44.
Christian S, Kraas J, Conway WF. Musculoskeletal infections. Semin Roentgenol. 2007;42(2):92–101.PubMedCrossRef
45.
• Lefevre S, Ruimy D, Jehl F, et al. Septic arthritis: monitoring with USPIO-enhanced Macrophage MR imaging. Radiology. 2011;258(3):722–8. This paper discusses a new imaging tool to diagnose and monitor response to antibiotic therapy in septic arthritis.PubMedCrossRef
46.
Ravindran V, Logan I, Bourke BE. Medical vs. surgical treatment for the native joint in septic arthritis: a 6-year, single UK academic centre experience. Rheumatology (Oxford). 2009;48:1320–2.CrossRef
47.
Stengel D, Bauwens K, Sehouli J, et al. Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. Lancet Infect Dis. 2001;1(3):175–88.PubMedCrossRef
48.
Falagas ME, Giannopoulou KP, Ntziora F, Papagelopoulos PJ. Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence. Int J Antimicrob Agents. 2007;30(3):202–9.PubMedCrossRef
49.
Falagas ME, Siempos II, Papagelopoulos PJ, Vardakas KZ. Linezolid for the treatment of adults with bone and joint infections. Int J Antimicrob Agents. 2007;29(3):233–9.PubMedCrossRef
50.
51.
Livermore DM, Canton R, Gniadkowski M, et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother. 2006;59(2):165–74.PubMedCrossRef
52.
Schelenz S, Bramham K, Goldsmith D. Septic arthritis due to extended spectrum beta lactamase producing Klebsiella pneumoniae. Joint Bone Spine. 2007;74(3):275–8.PubMedCrossRef
53.
Bean D, Krahe D, Wareham D. Antimicrobial resistance in community and nosocomial Escherichia coli urinary tract isolates, London 2005–2006. Ann Clin Microbiol Antimicrob. 2008;7(1):13.PubMedCrossRef
54.
Borg MA, Sande-Bruinsma N, Scicluna E, et al. Antimicrobial resistance in invasive strains of Escherichia coli from southern and eastern Mediterranean laboratories. Clin Microbiol Infect. 2008;14(8):789–96.PubMedCrossRef
55.
Ballock RTM, Newton POM, Evans SJM, et al. A comparison of early versus late conversion from intravenous to oral therapy in the treatment of septic arthritis. J Pediatr Orthop. 2009;29(6):636–42.PubMedCrossRef
56.
Jain S, Tittal P, Rohilla N, et al. Acute septic arthritis revisited: a prospective study in 93 patients correlating C-reactive protein levels with duration of intravenous antibiotic therapy, clinical and radiological outcomes. Eur J Orthop Surg Traumatol. 2009;19(7):447–55.CrossRef
57.
•• Harel LM, Prais DM, Bar-On EM, et al. Dexamethasone therapy for septic arthritis in children: results of a randomized double-blind Placebo-controlled study. J Pediatr Orthop. 2011;31(2):211–5. This paper discusses the role of corticosteroids in septic arthritis.PubMedCrossRef
58.
Forsman H, Andreasson E, nnheim K, et al. European Journal of Clinical Investigation 2010 Mar; Conference(var.pagings):44–5.
59.
Puliti M, von Hunolstein C, Bistoni F, et al. The beneficial effect of interleukin-12 on arthritis induced by group B streptococci is mediated by interferon-γ and interleukin-10 production. Arthritis Rheum. 2002;46(3):806–17.PubMedCrossRef
60.
• Bruins MJ, Zwiers JH, Verheyen CCPM, Wolfhagen MJHM. In vitro study of the antimicrobial effects of radiological contrast agents used in arthrography. J Bone Joint Surg Br. 2011;93-B(1):126–30. This paper discusses a potential novel adjunctive therapy for septic arthritis.CrossRef
61.
Verdrengh M, Carlsten H, Ohlsson C, Tarkowski A. Addition of bisphosphonate to antibiotic and anti-inflammatory treatment reduces bone resorption in experimental Staphylococcus aureus-induced arthritis. J Orthop Res. 2007;25(3):304–10.PubMedCrossRef
Metadata
Title
What’s New in the Management of Bacterial Septic Arthritis?
Authors
Sumeet Chander
Gerald Coakley
Publication date
01-10-2011
Publisher
Current Science Inc.
Published in
Current Infectious Disease Reports / Issue 5/2011
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-011-0201-0

Other articles of this Issue 5/2011

Current Infectious Disease Reports 5/2011 Go to the issue

ReviewPaper

Antibiotic Therapy in Neonatal and Pediatric Septic Shock

ReviewPaper

When and How to Cover for Resistant Gram-Negative Bacilli in Severe Sepsis and Septic Shock

ReviewPaper

Early and Adequate Antibiotic Therapy in the Treatment of Severe Sepsis and Septic Shock

ReviewPaper

When and How to Cover for Fungal Infections in Patients with Severe Sepsis and Septic Shock

ReviewPaper

Appropriate Antibiotic Dosage Levels in the Treatment of Severe Sepsis and Septic Shock

ReviewPaper

Soft Tissue Infections Caused by Marine Bacterial Pathogens: Epidemiology, Diagnosis, and Management
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits